Patents by Inventor Donald Rao

Donald Rao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11338749
    Abstract: An automotive vehicle includes a body having fore and aft portions. The vehicle includes a bumper beam coupled to the vehicle body proximate the fore portion and a heat exchanger disposed aft of the bumper beam. A fascia assembly is coupled to the vehicle body and extends about the bumper beam. The fascia assembly includes a fascia inlet configured to direct an airflow from the exterior of the fascia assembly to the interior of the fascia assembly. An energy absorption member is disposed between the fascia and the bumper beam. An air passage extends through at least one of the bumper beam and the energy absorption member. The air passage extends from an air passage inlet to an air passage outlet. The air passage inlet is positioned downstream of the fascia inlet with respect to the airflow, and the air passage outlet being positioned upstream of the heat exchanger.
    Type: Grant
    Filed: September 3, 2020
    Date of Patent: May 24, 2022
    Assignee: GM GLOBAL TECHNOLOGY OPERATIONS LLC
    Inventors: Jacob Wright, Changyoung Heo, Vinayshankar L. Virupaksha, Trevor T. Winch, Donald M. Jamison, Srinivasa Rao Vaddiraju, Amlanjyoti Barman
  • Publication number: 20190201848
    Abstract: The present invention includes a filter apparatus including a filtration unit; and a collection chamber in fluid communication with the filtration unit; wherein a vacuum draws the biological fluid through the apparatus; and wherein selected biological material comprised by the biological fluid is separated from a remainder of the biological fluid.
    Type: Application
    Filed: January 2, 2019
    Publication date: July 4, 2019
    Inventor: Donald Rao
  • Patent number: 10253331
    Abstract: Compositions and methods for cancer treatment are disclosed herein. More specifically, the present invention describes an autologous cancer vaccine genetically modified for Furin knockdown and GM-CSF expression. The vaccine described herein attenuates the immunosuppressive activity of TGF-? through the use of bi-functional shRNAs to knock down the expression of furin in cancer cells, and to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: April 9, 2019
    Assignee: GRADALIS, INC.
    Inventors: John J. Nemunaitis, Neil Senzer, Phillip B. Maples, Donald Rao
  • Publication number: 20180073038
    Abstract: Compositions and methods for cancer treatment are disclosed herein. More specifically, the present invention describes an autologous cancer vaccine genetically modified for Furin knockdown and GM-CSF expression. The vaccine described herein attenuates the immunosuppressive activity of TGF-? through the use of bi-functional shRNAs to knock down the expression of furin in cancer cells, and to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene.
    Type: Application
    Filed: August 29, 2017
    Publication date: March 15, 2018
    Inventors: John J. NEMUNAITIS, Neil SENZER, Phillip B. MAPLES, Donald RAO
  • Patent number: 9914977
    Abstract: In certain preferred embodiments, the invention provides methods for treating cancer, which comprise (a) obtaining a specimen of cancer tissue from a patient; (b) obtaining a specimen of normal tissue in the proximity of the cancer tissue from such patient; (c) extracting total protein and RNA from the cancer tissue and normal tissue; (d) obtaining a protein expression profile of the cancer tissue and normal tissue using 2D DIGE and mass spectrometry; (e) identifying proteins that are expressed in such cancer tissue at significantly different levels than in the normal tissue; (f) obtaining a gene expression profile of the cancer tissue and normal tissue using microarray technology and comparing the results thereof to the protein expression profile; (g) prioritizing over-expressed proteins by assessing the connectivity thereof to other cancer-related or stimulatory proteins; (h) designing an appropriate RNA interference expression cassette to, directly or indirectly, modulate the expression of genes encoding s
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: March 13, 2018
    Assignee: GRADALIS, INC.
    Inventors: David M. Shanahan, John J. Nemunaitis, Neil Senzer, Phillip B. Maples, Donald Rao
  • Patent number: 9790518
    Abstract: Compositions and methods for cancer treatment are disclosed herein. More specifically, the present invention describes an autologous cancer vaccine genetically modified for Furin knockdown and GM-CSF expression. The vaccine described herein attenuates the immunosuppressive activity of TGF-? through the use of bi-functional shRNAs to knock down the expression of furin in cancer cells, and to segment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: October 17, 2017
    Assignee: GRADALIS, INC.
    Inventors: John J. Nemunaitis, Neil Senzer, Phillip B. Maples, Donald Rao
  • Patent number: 9695422
    Abstract: Compositions and methods to attenuate the immunosuppressive activity of TGF-? through the use of bi-functional shRNAs is described herein. The bi-functional shRNAs of the present invention knocks down the expression of furin in cancer cells to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: July 4, 2017
    Assignee: GRADALIS, INC.
    Inventors: John J. Nemunaitis, Neil Senzer, Phillip B. Maples, Donald Rao
  • Publication number: 20170175124
    Abstract: In certain embodiments, the invention provides methods for treating cancer, comprising: obtaining a specimen of cancer tissue and normal tissue from a patient; extracting total protein; obtaining a protein expression profile; identifying over-expressed proteins; comparing the protein expression profile to a gene expression profile; identifying at least one prioritized protein target; designing a first RNA interference expression cassette; designing a first RNA interference expression cassette to modulate the expression of at least one gene encoding; incorporating the first cassette into a delivery vehicle; and providing a patient with an effective amount of the first delivery vehicle.
    Type: Application
    Filed: December 21, 2016
    Publication date: June 22, 2017
    Inventors: David M. Shanahan, John J. Nemunaitis, Neil Senzer, Phillip B. Maples, Donald Rao
  • Patent number: 9683237
    Abstract: The present invention includes compositions and methods for making and using a RNAi capable of reducing expression of two or more genes, comprising: a first RNAi molecule that reduces the expression of a first target gene; a second RNAi molecule that reduces the expression of the first or a second target gene; and optionally a third RNAi molecule that reduces the expression of the first, the second, or a third target gene, wherein the RNAi molecules reduce the expression level of, e.g., mutated KRAS, SRC-3, EGFR, PIK3, NCOA3, or ERalpha1, and can be, e.g., miRNAs, shRNAs, or bifunctional shRNAs.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: June 20, 2017
    Assignees: STRIKE BIO, INC., BAYLOR COLLEGE OF MEDICINE
    Inventors: Donald Rao, John Nemunaitis, Bert W. O'Malley, David Lonard
  • Publication number: 20170073768
    Abstract: In certain preferred embodiments, the invention provides methods for treating cancer, which comprise (a) obtaining a specimen of cancer tissue from a patient; (b) obtaining a specimen of normal tissue in the proximity of the cancer tissue from such patient; (c) extracting total protein and RNA from the cancer tissue and normal tissue; (d) obtaining a protein expression profile of the cancer tissue and normal tissue using 2D DIGE and mass spectrometry; (e) identifying proteins that are expressed in such cancer tissue at significantly different levels than in the normal tissue; (f) obtaining a gene expression profile of the cancer tissue and normal tissue using microarray technology and comparing the results thereof to the protein expression profile; (g) prioritizing over-expressed proteins by assessing the connectivity thereof to other cancer-related or stimulatory proteins; (h) designing an appropriate RNA interference expression cassette to, directly or indirectly, modulate the expression of genes encoding s
    Type: Application
    Filed: June 3, 2016
    Publication date: March 16, 2017
    Inventors: David M. Shanahan, John J. Nemunaitis, Neil Senzer, Phillip B. Maples, Donald Rao
  • Patent number: 9556431
    Abstract: The present invention relates to certain novel shRNA molecules and methods of use thereof. According to certain embodiments of the present invention, methods for reducing the expression level of a target gene are provided. Such methods generally comprise providing a cell with one or more precursor nucleic acid sequences that encode two or more RNA molecules. A first RNA molecule comprises a double stranded sequence, which includes a guide strand sequence that is complementary to a portion of an mRNA transcript encoded by the target gene. In addition, a second RNA molecule comprises a second double stranded sequence, which includes a second guide strand sequence that is partially complementary to a portion of the mRNA transcript encoded by the target gene. Preferably, the second guide strand sequence comprises one or more bases that are mismatched with a nucleic acid sequence of the mRNA transcript encoded by the target gene.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: January 31, 2017
    Assignee: Strike Bio, Inc.
    Inventor: Donald Rao
  • Patent number: 9528991
    Abstract: In certain embodiments, the invention provides methods for treating cancer, comprising: obtaining a specimen of cancer tissue and normal tissue from a patient; extracting total protein; obtaining a protein expression profile; identifying over-expressed proteins; comparing the protein expression profile to a gene expression profile; identifying at least one prioritized protein target; designing a first RNA interference expression cassette; designing a first RNA interference expression cassette to modulate the expression of at least one gene encoding; incorporating the first cassette into a delivery vehicle; and providing a patient with an effective amount of the first delivery vehicle.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: December 27, 2016
    Assignee: GRADALIS, INC.
    Inventors: David M. Shanahan, John J. Nemunaitis, I, Neil Senzer, Phillip B. Maples, Donald Rao
  • Publication number: 20160333351
    Abstract: The present invention includes compositions and methods for making and using a bifunctional shRNAs capable of reducing an expression of a K-ras gene, e.g., a mutated K-ras gene, wherein at least one target site sequence of the bifunctional RNA molecule is located within the K-ras gene and wherein the bifunctional RNA molecule is capable of activating a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of K-ras.
    Type: Application
    Filed: April 28, 2016
    Publication date: November 17, 2016
    Inventors: Donald Rao, Zhaohui Wang, John J. Nemunaitis, Neil Senzer
  • Publication number: 20160194640
    Abstract: A method for designing a bi-shRNA expression cassette encoding a bi-shRNA comprising: selecting one or more target site sequences; providing a backbone sequence comprising a first and a second stem-loop structure, inserting a first passenger strand and a second passenger strand and providing for synthesis of the bi-shRNA expression cassette.
    Type: Application
    Filed: March 21, 2016
    Publication date: July 7, 2016
    Inventor: Donald Rao
  • Patent number: 9382589
    Abstract: In certain preferred embodiments, the invention provides methods for treating cancer, which comprise (a) obtaining a specimen of cancer tissue from a patient; (b) obtaining a specimen of normal tissue in the proximity of the cancer tissue from such patient; (c) extracting total protein and RNA from the cancer tissue and normal tissue; (d) obtaining a protein expression profile of the cancer tissue and normal tissue using 2D DIGE and mass spectrometry; (e) identifying proteins that are expressed in such cancer tissue at significantly different levels than in the normal tissue; (f) obtaining a gene expression profile of the cancer tissue and normal tissue using microarray technology and comparing the results thereof to the protein expression profile; (g) prioritizing over-expressed proteins by assessing the connectivity thereof to other cancer-related or stimulatory proteins; (h) designing an appropriate RNA interference expression cassette to, directly or indirectly, modulate the expression of genes encoding s
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: July 5, 2016
    Assignee: GRADALIS, INC.
    Inventors: David Shanahan, John J. Nemunaitis, Neil Senzer, Phillip B. Maples, Donald Rao
  • Patent number: 9353373
    Abstract: The present invention includes compositions and methods for making and using a bifunctional shRNAs capable of reducing an expression of a K-ras gene, e.g., a mutated K-ras gene, wherein at least one target site sequence of the bifunctional RNA molecule is located within the K-ras gene and wherein the bifunctional RNA molecule is capable of activating a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of K-ras.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: May 31, 2016
    Assignee: STRIKE BIO, INC.
    Inventors: Donald Rao, Zhaohui Wang, John J. Nemunaitis, Neal Senzer
  • Patent number: 9290763
    Abstract: A method for designing a bi-shRNA expression cassette encoding a bi-shRNA comprising: selecting one or more target site sequences; providing a backbone sequence comprising a first and a second stem-loop structure, inserting a first passenger strand and a second passenger strand and providing for synthesis of the bi-shRNA expression cassette.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: March 22, 2016
    Assignee: STRIKE BIO, Inc.
    Inventor: Donald Rao
  • Publication number: 20150368651
    Abstract: Compositions and methods to attenuate the immunosuppressive activity of TGF-? through the use of bi-functional shRNAs is described herein. The bi-functional shRNAs of the present invention knocks down the expression of furin in cancer cells to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene.
    Type: Application
    Filed: September 3, 2015
    Publication date: December 24, 2015
    Inventors: John J. Nemunaitis, Neil Senzer, Phillip B. Maples, Donald Rao
  • Publication number: 20150368640
    Abstract: The present invention relates to certain novel shRNA molecules and methods of use thereof. According to certain embodiments of the present invention, methods for reducing the expression level of a target gene are provided. Such methods generally comprise providing a cell with one or more precursor nucleic acid sequences that encode two or more RNA molecules. A first RNA molecule comprises a double stranded sequence, which includes a guide strand sequence that is complementary to a portion of an mRNA transcript encoded by the target gene. In addition, a second RNA molecule comprises a second double stranded sequence, which includes a second guide strand sequence that is partially complementary to a portion of the mRNA transcript encoded by the target gene. Preferably, the second guide strand sequence comprises one or more bases that are mismatched with a nucleic acid sequence of the mRNA transcript encoded by the target gene.
    Type: Application
    Filed: June 27, 2014
    Publication date: December 24, 2015
    Inventor: Donald Rao
  • Publication number: 20150329873
    Abstract: Compositions and methods for cancer treatment are disclosed herein. More specifically the present invention describes an autologous cancer vaccine genetically modified for Furin knockdown and GM-CSF expression. The vaccine described herein attenuates the immunosuppressive activity of TGF-? through the use of bi-functional shRNAs to knock down the expression of furin in cancer cells, and to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene.
    Type: Application
    Filed: July 31, 2015
    Publication date: November 19, 2015
    Inventors: John J. Nemunaitis, Neil Senzer, Phillip B. Maples, Donald Rao